Brandon Blue on Muck Rack

Brandon Blue

Des Moines
As seen in: WHO-AM (Des Moines, IA), Nature, Medscape, Metro Weekly, ONCOLOGY journal, OncLive, Oncology News Central, Iowa Agribusiness Radio Network
Listener, Writer, and infant-level Francophone.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Brandon

Contact Brandon, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

|
By Laura B. Oswald, Xiaoyin Li, Lisa M. Gudenkauf, Brent J Small, Brian Gonzalez, Aasha I. Hoogland, Oanh K. Nguyen, Sylvia L. Crowder, Nathan Parker, Tiffany L. Carson, Christine Vinci, Rachid Baz, Kenneth H Shain, Brandon Blue, Ariel Grajales-Cruz, Brandon Kale, Fabiana Perna, Melissa Alsina, Ciara L Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Frederick Locke, Heather Jim, Lauren C. Peres, Doris Hansen, Gabe De Avila, David Scheiber-Camoretti, Yvelise Rodriguez, Kristy Matte, David Kaldas
| Nature Verified
Abstract This was the first study to assess patient-reported outcome (PRO) trajectories among patients with relapsed/refractory multiple myeloma (RRMM) receiving standard of care chimeric antigen receptor T-cell therapy (CAR-T) and to compare PRO trajectories by treatment group, idecabtagene vicleucel (ide-cel) vs. ciltacabtagene autoleucel (cilta-cel).
Open in Who Shared Issue with article?

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium

|
By Andrew J. Portuguese, James Davis, Shahzad Raza, Omar Castaneda Puglianini, Ciara L Freeman, Melissa Alsina, Corbin Wright, Brandon Blue, Rachid Baz, Kenneth H Shain, Utkarsh Goel, Jack Khouri, Faiz Anwer, Hossam Ali, Oren Pasvolsky, Mahmoud R. Gaballa, Damian Mikulski, Lindsay Fogel, Eli Zolotov, Aishwarya Sannareddy, Aimaz Afrough, Larry D. Jr, Kelley Julian, Danai Dima, Rahul Banerjee, Emily Liang, Raffaella Cassano, Megan Herr Verified, Hamza Hassan, Leyla O. Shune, Jeries Kort, Shonali Midha, Omar Nadeem, Surbhi Sidana, Yi Lin, Frederick Locke, Doris Hansen, Douglas Sborov, Noa Biran, Ariel Grajales-Cruz, Hector Garcia-Pleitez
| Nature Verified
Abstract Elranatamab, a BCMA-CD3 bispecific antibody, has demonstrated robust activity in relapsed/refractory multiple myeloma (RRMM), but real-world outcomes remain poorly defined. We conducted a multicenter retrospective study of 130 patients treated with commercial elranatamab across nine U.S. academic centers. The cohort was heavily pretreated (91% triple-class refractory, 49% penta-refractory), with 49% previously exposed to BCMA-targeted therapies.
Open in Who Shared Issue with article?

Big Step Toward Finding the Cure for Multiple Myeloma? “Wonderful” Data at ASCO 2025

|
By Brandon Blue
| Oncology News Central Verified
First-in-human trials of trispecific treatments for multiple myeloma and long-term data on CAR-T use are among the highlights at the American Society of Clinical Oncology Annual Meeting, says Brandon Blue, MD, assistant member of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida. In terms of trispecific drugs, “I’ll tell you that is really going to be the biggest step that we have now to finding the cure for multiple myeloma,” Dr. Blue explained.
Open in Who Shared Issue with article?
See all 36 licensed articles (38 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified